BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 11112219)

  • 1. Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations.
    Werness BA; Ramus SJ; Whittemore AS; Garlinghouse-Jones K; Oakley-Girvan I; Dicioccio RA; Tsukada Y; Ponder BA; Piver MS
    Hum Pathol; 2000 Nov; 31(11):1420-4. PubMed ID: 11112219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry.
    Werness BA; Ramus SJ; DiCioccio RA; Whittemore AS; Garlinghouse-Jones K; Oakley-Girvan I; Tsukada Y; Harrington P; Gayther SA; Ponder BA; Piver MS
    Int J Gynecol Pathol; 2004 Jan; 23(1):29-34. PubMed ID: 14668547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
    Schorge JO; Mahoney NM; Miller DS; Coleman RL; Muller CY; Euhus DM; Tomlinson GE
    Gynecol Oncol; 2001 Nov; 83(2):383-7. PubMed ID: 11606101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Germline mutation of BRCA1 gene in Polish families with strong aggregation of breast and/or ovarian cancer based on coding sequence analysis using the SSCP method].
    Byrski T
    Ann Acad Med Stetin; 2003; 49():27-43. PubMed ID: 15552838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hereditary ovarian cancer.
    Prat J; Ribé A; Gallardo A
    Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.
    Brozek I; Ochman K; Debniak J; Morzuch L; Ratajska M; Stepnowska M; Stukan M; Emerich J; Limon J
    Gynecol Oncol; 2008 Feb; 108(2):433-7. PubMed ID: 17997147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
    Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
    Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.
    Rubin SC; Benjamin I; Behbakht K; Takahashi H; Morgan MA; LiVolsi VA; Berchuck A; Muto MG; Garber JE; Weber BL; Lynch HT; Boyd J
    N Engl J Med; 1996 Nov; 335(19):1413-6. PubMed ID: 8875917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study.
    Smith SA; Richards WE; Caito K; Hanjani P; Markman M; DeGeest K; Gallion HH
    Gynecol Oncol; 2001 Dec; 83(3):586-92. PubMed ID: 11733976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.
    Quenneville LA; Phillips KA; Ozcelik H; Parkes RK; Knight JA; Goodwin PJ; Andrulis IL; O'Malley FP
    Cancer; 2002 Nov; 95(10):2068-75. PubMed ID: 12412159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer.
    Gotlieb WH; Chetrit A; Menczer J; Hirsh-Yechezkel G; Lubin F; Friedman E; Modan B; Ben-Baruch G;
    Gynecol Oncol; 2005 Jun; 97(3):780-3. PubMed ID: 15893369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The spectrum and incidence of BRCA1 pathogenic mutations in Slovak breast/ovarian cancer families.
    Konecny M; Vizvaryova M; Weismanova E; Ilencikova D; Mlkva I; Weismann P; Machackova G; Kausitz J
    Neoplasma; 2007; 54(2):137-42. PubMed ID: 17319787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline mutations in the BRCA1 gene predisposing to breast and ovarian cancers in Upper Silesia population.
    Grzybowska E; Siemińska M; Zientek H; Kalinowska E; Michalska J; Utracka-Hutka B; Rogozińska-Szczepka J; Kaźmierczak-Maciejewska M
    Acta Biochim Pol; 2002; 49(2):351-6. PubMed ID: 12362976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian patients with breast carcinoma through hospital-based screening.
    Palomba G; Pisano M; Cossu A; Budroni M; Dedola MF; Farris A; Contu A; Baldinu P; Tanda F; Palmieri G
    Cancer; 2005 Sep; 104(6):1172-9. PubMed ID: 16047344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon?
    Balmaña J; Díez O; Campos B; Majewski M; Sanz J; Alonso C; Baiget M; Garber JE
    Breast Cancer Res Treat; 2005 Aug; 92(3):273-7. PubMed ID: 16155798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families.
    Kang HC; Kim IJ; Park JH; Kwon HJ; Won YJ; Heo SC; Lee SY; Kim KH; Shin Y; Noh DY; Yang DH; Choe KJ; Lee BH; King SB; Park JG
    Hum Mutat; 2002 Sep; 20(3):235. PubMed ID: 12204006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.